window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Artificial Intelligence,Biotech,Drug discovery,Oncology,Partnerships & Funding,Research & Development,Technology and platforms

    Evogene partners QUT on AI drug discovery for lung cancer resistance

    Evogene Ltd has partnered with Queensland University of Technology to [...]

    February 19, 2026
  • Biotech,Mergers & Acquisitions,Opthalmology,Research & Development,Technology and platforms

    Axol Bioscience acquires Newcells ophthalmology business to expand retinal organoid portfolio

    Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, [...]

    February 19, 2026
  • Biotech,Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Rare Diseases,Research & Development

    Polaryx therapeutics selects contract research organization for SOTERIA phase 2 basket trial

    Polaryx Therapeutics, Inc has selected a leading contract research organization [...]

    February 18, 2026
  • Clinical Trials,Infectious Diseases,Pharmaceuticals and therapeutics,Research & Development

    ViiV Healthcare highlights ultra long-acting HIV pipeline and Phase 1 data at CROI 2026

    ViiV Healthcare will present new data from its long-acting and [...]

    February 18, 2026
  • Artificial Intelligence,Clinical Development,Data Management,Digital Health,Healthcare leadership,Pharmaceuticals and therapeutics,Research & Development

    AI and medical affairs strategy set to redefine life sciences in 2026

    Artificial intelligence, shifting healthcare professional behaviour and rising pressure on [...]

    February 18, 2026
  • Artificial Intelligence,Biotech,Drug Development,Partnerships & Funding,Research & Development,Technology and platforms

    Nuclera and leadXpro partner on AI-guided workflow for membrane protein drug discovery

    Nuclera and leadXpro have entered a scientific partnership to develop [...]

    February 17, 2026
  • Clinical Development,Clinical Trials,European biotech,Mental health,Neurosciences,Research & Development

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    February 17, 2026
  • Clinical Trials,Oncology,Orphan drugs,Pharmaceuticals and therapeutics,Research & Development

    Oncoinvent to present 24-month Phase 1 ovarian cancer data for Radspherin at ESGO 2026

    Oncoinvent will present final 24-month follow-up data from its Phase [...]

    February 18, 2026
  • Cell & Gene Therapy,Clinical Development,Genetic Diseases,Research & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    February 18, 2026
  • Diagnostics,Genomics and sequencing,Research & Development,Technology and platforms

    New England Biolabs launches Monarch Mag Cell-free DNA extraction kit for scalable cfDNA isolation

    New England Biolabs has launched the Monarch Mag Cell-free DNA [...]

    February 15, 2026
Previous567Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top